- Home
- RPRX vs MKL Comparison
RPRX vs MKL Comparison
Compare RPRX & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RPRX | MKL |
|---|---|---|
| Founded | 1996 | 1930 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 24.8B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RPRX | MKL |
|---|---|---|
| Price | $58.55 | $1,837.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $51.40 | ★ $2,100.00 |
| AVG Volume (30 Days) | ★ 2.9M | 62.7K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.71 | ★ 73.57 |
| Revenue | $2,378,193,000.00 | ★ $15,513,233,000.00 |
| Revenue This Year | $38.63 | N/A |
| Revenue Next Year | $4.73 | $2.26 |
| P/E Ratio | $83.41 | ★ $25.04 |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $34.63 | $1,719.41 |
| 52 Week High | $60.44 | $2,207.59 |
Technical Indicators
Market Signals| Indicator | RPRX | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 53.25 | 35.09 |
| Support Level | $55.66 | $1,740.21 |
| Resistance Level | $58.84 | $1,876.58 |
| Average True Range (ATR) | 1.42 | 40.17 |
| MACD | -0.11 | -13.34 |
| Stochastic Oscillator | 46.94 | 4.24 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About MKL Markel Group Inc.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.